Stimulatory lipids accumulate in the mouse liver within 30min of contact sensitization to facilitate the activation of naïve iNKT cells in a CD1d-dependent fashion

Scandinavian Journal of Immunology

Volumn 74, Issue 1, 2011, Pages 52-61

  Dey, N ^a   Szczepanik, M ^b   Lau, K ^a   Majewska Szczepanik, M ^b   Askenase, P W ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; CD1D ANTIGEN; LIPID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CELL MIGRATION; CONTACT ALLERGY; CONTACT SENSITIZATION; CONTROLLED STUDY; CYTOKINE RELEASE; EFFECTOR CELL; IMMUNE RESPONSE; INFLAMMATION; KNOCKOUT MOUSE; LIPID STORAGE; LIVER; LIVER CELL; MONONUCLEAR CELL; MOUSE; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; SKIN ALLERGY;

ADOPTIVE TRANSFER; ANIMALS; ANTIGENS, CD1D; DERMATITIS, CONTACT; HEPATOCYTES; LIPIDS; LIVER; LYMPHOCYTE ACTIVATION; MICE; MICE, KNOCKOUT; NATURAL KILLER T-CELLS;

EID: 79958732175     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2011.02540.x     Document Type: Article

References (45)

1. Kronenberg M, Gapin L. The unconventional lifestyle of NKT cells. Nat Rev Immunol 2002;2:557-68.
2. Brigl M, Brenner MB. CD1: antigen presentation and T cell function. Annu Rev Immunol 2004;22:817-90.
3. Godfrey DI, Kronenberg M. Going both ways: immune regulation via CD1d-dependent NKT cells. J Clin Invest 2004;114:1379-88.
4. Stetson DB, Mohrs M, Reinhardt RL et al. Constitutive cytokine mRNAs mark natural killer (NK) and NK T cells poised for rapid effector function. J Exp Med 2003;198:1069-76.
5. Miyagi T, Takehara T, Uemura A et al. Absence of invariant natural killer T cells deteriorates liver inflammation and fibrosis in mice fed high-fat diet. J Gastroenterol 2010;45:1247-54.
6. Maher JJ, Leon P, Ryan JC. Beyond insulin resistance: innate immunity in nonalcoholic steatohepatitis. Hepatology 2008;48:670-8.
7. Dupuis G. Allergic Contact Dermatitis to Simple Chemicals: A Molecular Approach. New York: M. Dekker, 1982. ISBN 0824714687.
8. Campos RA, Szczepanik M, Iliopoulou P, Akahira-Azuma M, Askenase PW. NKT cell derived IL-4 activates B-1 cells to initiate contact sensitivity (CS). FASEB J 2001;15:A693.
9. Campos RA, Szczepanik M, Itakura A et al. Cutaneous immunization rapidly activates liver invariant Valpha14 NKT cells stimulating B-1 B cells to initiate T cell recruitment for elicitation of contact sensitivity. J Exp Med 2003;198:1785-96.
10. Campos RA, Szczepanik M, Itakura A et al. Interleukin-4-dependent innate collaboration between iNKT cells and B-1 B cells controls adaptative contact sensitivity. Immunology 2006;117:536-47.
11. Itakura A, Szczepanik M, Campos RA et al. An hour after immunization peritoneal B-1 cells are activated to migrate to lymphoid organs where within 1day they produce IgM antibodies that initiate elicitation of contact sensitivity. J Immunol 2005;175:7170-8.
12. Lepoittevin J, Leblond I. Hapten-peptide-T cell receptor interactions: molecular basis for the recognition of haptens by T lymphocytes. Eur J Dermatol 1997;7:151-4.
13. Peeler JS, Niederkorn JY. Antigen presentation by Langerhans cells in vivo: donor-derived Ia+ Langerhans cells are required for induction of delayed-type hypersensitivity but not for cytotoxic T lymphocyte responses to alloantigens. J Immunol 1986;136:4362-71.
14. Geba GP, Ptak W, Anderson GM et al. Delayed-type hypersensitivity in mast cell-deficient mice: dependence on platelets for expression of contact sensitivity. J Immunol 1996;157:557-65.
15. van Loveren H, Meade R, Askenase PW. An early component of delayed-type hypersensitivity mediated by T cells and mast cells. J Exp Med 1983;157:1604-17.
16. Matsuda H, Ushio H, Geba GP, Askenase PW. Human platelets can initiate T cell-dependent contact sensitivity through local serotonin release mediated by IgE antibodies. J Immunol 1997;158:2891-7.
17. Meade R, Van Lovern H, Parmentier H, Iverson GM, Askenase PW. The antigen-binding T cell factor PCl-F sensitizes mast cells for in vitro release of serotonin. Comparison with monoclonal IgE antibody. J Immunol 1988;141:2704-13.
18. Askenase PW, Bursztajn S, Gershon MD, Gershon RK. T cell-dependent mast cell degranulation and release of serotonin in murine delayed-type hypersensitivity. J Exp Med 1980;152:1358-74.
19. Hwang JM, Yamanouchi J, Santamaria P, Kubes P. A critical temporal window for selectin-dependent CD4+ lymphocyte homing and initiation of late-phase inflammation in contact sensitivity. J Exp Med 2004;199:1223-34.
20. Norman MU, Hulliger S, Colarusso P, Kubes P. Multichannel fluorescence spinning disk microscopy reveals early endogenous CD4 T cell recruitment in contact sensitivity via complement. J Immunol 2008;180:510-21.
21. Norman MU, Hwang J, Hulliger S et al. Mast cells regulate the magnitude and the cytokine microenvironment of the contact hypersensitivity response. Am J Pathol 2008;172:1638-49.
22. Harari OA, McHale JF, Marshall D et al. Endothelial cell E- and P-selectin up-regulation in murine contact sensitivity is prolonged by distinct mechanisms occurring in sequence. J Immunol 1999;163:6860-6.
23. Askenase PW. Yes T cells, but three different T cells (alphabeta, gammadelta and NK T cells), and also B-1 cells mediate contact sensitivity. Clin Exp Immunol 2001;125:345-50.
24. Kawano T, Cui J, Koezuka Y et al. CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science 1997;278:1626-9.
25. Zhou D, Mattner J, Cantu C et al. Lysosomal glycosphingolipid recognition by NKT cells. Science 2004;306:1786-9.
26. Chen J, Trounstine M, Alt FW et al. Immunoglobulin gene rearrangement in B cell deficient mice generated by targeted deletion of the JH locus. Int Immunol 1993;5:647-56.
27. Morita M, Motoki K, Akimoto K et al. Structure-activity relationship of alpha-galactosylceramides against B16-bearing mice. J Med Chem 1995;38:2176-87.
28. Trobonjaca Z, Leithäuser F, Möller P, Schirmbeck R, Reimann J. Activating immunity in the liver. I. Liver dendritic cells (but not hepatocytes) are potent activators of IFN-gamma release by liver NKT cells. J Immunol 2001;167:1413-22.
29. Mandal M, Chen XR, Alegre ML et al. Tissue distribution, regulation and intracellular localization of murine CD1 molecules. Mol Immunol 1998;35:525-36.
30. Mendiratta SK, Martin WD, Hong S, Boesteanu A, Joyce S, Van Kaer L. CD1d1 mutant mice are deficient in natural T cells that promptly produce IL-4. Immunity 1997;6:469-77.
31. Toews GB, Bergstresser PR, Streilein JW. Epidermal Langerhans cell density determines whether contact hypersensitivity or unresponsiveness follows skin painting with DNFB. J Immunol 1980;124:445-53.
32. Hameg A, Apostolou I, Leite-De-Moraes M et al. A subset of NKT cells that lacks the NK1.1 marker, expresses CD1d molecules, and autopresents the alpha-galactosylceramide antigen. J Immunol 2000;165:4917-26.
33. Cheng L, Ueno A, Cho S et al. Efficient activation of Valpha14 invariant NKT cells by foreign lipid antigen is associated with concurrent dendritic cell-specific self recognition. J Immunol 2007;178:2755-62.
34. Monteiro M, Almeida CF, Caridade M et al. Identification of regulatory Foxp3+ invariant NKT cells induced by TGF-beta. J Immunol 2010;185:2157-63.
35. Ellison CA, Taniguchi M, Fischer JMM, Hayglass KT, Gartner JG. Graft-versus-host disease in recipients of grafts from natural killer T cell-deficient (Jalpha281(-/-)) donors. Immunology 2006;119:338-47.
36. Yang J, Gao L, Liu Y et al. Adoptive therapy by transfusing expanded donor murine natural killer T cells can suppress acute graft-versus-host disease in allogeneic bone marrow transplantation. Transfusion 2010;50:407-17.
37. Motohashi S, Ishikawa A, Ishikawa E et al. A phase I study of in vitro expanded natural killer T cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res 2006;12:6079-86.
38. Giaccone G, Punt CJA, Ando Y et al. A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors. Clin Cancer Res 2002;8:3702-9.
39. Ishikawa A, Motohashi S, Ishikawa E et al. A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res 2005;11:1910-7.
40. Nieda M, Okai M, Tazbirkova A et al. Therapeutic activation of Valpha24+ Vbeta11+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity. Blood 2004;103:383-9.
41. Chang DH, Osman K, Connolly J et al. Sustained expansion of NKT cells and antigen-specific T cells after injection of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patients. J Exp Med 2005;201:1503-17.
42. Uchida T, Horiguchi S, Tanaka Y et al. Phase I study of alpha-galactosylceramide-pulsed antigen presenting cells administration to the nasal submucosa in unresectable or recurrent head and neck cancer. Cancer Immunol Immunother 2008;57:337-45.
43. Toura I, Kawano T, Akutsu Y, Nakayama T, Ochiai T, Taniguchi M. Cutting edge: inhibition of experimental tumor metastasis by dendritic cells pulsed with alpha-galactosylceramide. J Immunol 1999;163:2387-91.
44. Akutsu Y, Nakayama T, Harada M et al. Expansion of lung V alpha 14 NKT cells by administration of alpha-galactosylceramide-pulsed dendritic cells. Jpn J Cancer Res 2002;93:397-403.
45. Motohashi S, Kobayashi S, Ito T et al. Preserved IFN-alpha production of circulating Valpha24 NKT cells in primary lung cancer patients. Int J Cancer 2002;102:159-65.